Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care

Nov 29, 2007, 00:00 ET from Renal Solutions, Inc.

    WARRENDALE, Pa., Nov. 29 /PRNewswire/ -- Renal Solutions, Inc. (RSI)
 announced today that the Company has been acquired by Fresenius Medical
 Care AG & Co. KGaA. RSI will continue operations as a wholly owned
 subsidiary of Fresenius Medical Care, the largest integrated global
 provider of dialysis products and services. Peter DeComo will continue to
 lead RSI operations in Warrendale, PA and Oklahoma City, OK.
 
     Renal Solutions is the innovator in the field of sorbent dialysis
 therapy. The Company's sorbent technology is based on a more than 35-year
 history of proven dialysis therapy and enables flexible treatment options
 using only 6 liters of drinking water. RSI holds a number of key patents
 and other intellectual property related to sorbent dialysis therapy and has
 recently launched its Sorbent Management for Advanced Renal Replacement
 Therapy (SMARRT(TM)) platform.
 
     SMARRT therapy utilizes a gentle, patient-driven technology backed by
 over 6 million treatments. It enables short, standard or extended duration
 hemodialysis therapy using only 6 liters of drinking water without
 requiring the use of a water treatment system. The small dialysate quantity
 made possible by sorbent technology provides an inherent volume safety not
 possible with conventional hemodialysis technology. At the same time, it
 creates a dialysate flow rate of up to 400 ml/min., enabling the provision
 of highly effective dialysis. Advanced sorbent cartridges contain
 specialized sorbent compounds that regenerate fresh, high purity dialysate,
 eliminating the need for complex and costly water purification systems.
 
     "This acquisition validates the strategic importance of sorbent
 technology to the dialysis field," said Peter DeComo, President and CEO of
 Renal Solutions. "The combination of Renal Solutions and Fresenius Medical
 Care, the global leader in dialysis products and services, will maximize
 the value of sorbent therapy through rapid development of innovative
 products and services that would have been difficult to achieve as a small
 independent company," he continued. "The convergence of our respective
 resources will enhance the prospects for true innovative approaches,
 including portability and wearability, to further improve the service to
 patients requiring dialysis therapy worldwide."
 
     RSI is currently commercializing the Allient(R) Sorbent Hemodialysis
 System for chronic and acute hemodialysis applications. The Allient System
 will be the first dialysis system to bring SMARRT technology to the market,
 opening new treatment options to dialysis professionals and patients.
 
     The current RSI home use clinical study featuring the Allient System
 and sorbent technology will continue enrollment at multiple sites. The
 trial is designed to demonstrate patient ability to self-administer
 hemodialysis in the home using the FDA cleared system. In this research
 study, 25 dialysis participants will self-administer extended duration
 dialysis in the home.
 
     Morgan Stanley served as advisor to Renal Solutions for the
 transaction.
 
     About Renal Solutions, Inc
 
     Renal Solutions, Inc., a medical device and healthcare service company,
 is commercializing the Allient(R) Sorbent Hemodialysis System, a
 revolutionary technology/service solution for the chronic and acute
 dialysis market. The Allient System, brings SMARRT (Sorbent Management for
 Advanced Renal Replacement Therapy) therapy to the dialysis field, opening
 new treatment options to dialysis professionals and patients by virtue of
 its ability to provide short, standard or extended duration hemodialysis
 therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous
 clinical studies have shown that an increased cumulative dialysis dose
 results in better patient outcomes. The Allient System provides the
 increased dose advantage without the need for an independent water system
 or large volumes of sterile fluid. This translates into increased
 flexibility and convenience benefits.
 
     For more information about Renal Solutions visit the Company's website
 at www.renalsolutionsinc.com.
 
     This press release contains forward-looking statements, which if not
 based on historical facts, involve risks and uncertainties. Our actual
 results may differ materially from the results or events stated in the
 forward-looking statements, including, but not limited to, certain events
 not within the Company's control. Events which could cause results to
 differ include, failure to meet on-going developmental and manufacturing
 timelines, changing GMP requirements, the need for additional capital
 requirements, risks associated with the FDA/regulatory approval process,
 adverse changes to reimbursement for the Company's products/services and
 delays with respect to market acceptance of new products/services and
 technologies. Other risks may be detailed from time to time but the Company
 does not attempt to revise or update its forward- looking statements even
 if future experience or changes make it evident that any projected events
 or results expressed or implied therein will not be realized.
 
 
 

SOURCE Renal Solutions, Inc.
    WARRENDALE, Pa., Nov. 29 /PRNewswire/ -- Renal Solutions, Inc. (RSI)
 announced today that the Company has been acquired by Fresenius Medical
 Care AG & Co. KGaA. RSI will continue operations as a wholly owned
 subsidiary of Fresenius Medical Care, the largest integrated global
 provider of dialysis products and services. Peter DeComo will continue to
 lead RSI operations in Warrendale, PA and Oklahoma City, OK.
 
     Renal Solutions is the innovator in the field of sorbent dialysis
 therapy. The Company's sorbent technology is based on a more than 35-year
 history of proven dialysis therapy and enables flexible treatment options
 using only 6 liters of drinking water. RSI holds a number of key patents
 and other intellectual property related to sorbent dialysis therapy and has
 recently launched its Sorbent Management for Advanced Renal Replacement
 Therapy (SMARRT(TM)) platform.
 
     SMARRT therapy utilizes a gentle, patient-driven technology backed by
 over 6 million treatments. It enables short, standard or extended duration
 hemodialysis therapy using only 6 liters of drinking water without
 requiring the use of a water treatment system. The small dialysate quantity
 made possible by sorbent technology provides an inherent volume safety not
 possible with conventional hemodialysis technology. At the same time, it
 creates a dialysate flow rate of up to 400 ml/min., enabling the provision
 of highly effective dialysis. Advanced sorbent cartridges contain
 specialized sorbent compounds that regenerate fresh, high purity dialysate,
 eliminating the need for complex and costly water purification systems.
 
     "This acquisition validates the strategic importance of sorbent
 technology to the dialysis field," said Peter DeComo, President and CEO of
 Renal Solutions. "The combination of Renal Solutions and Fresenius Medical
 Care, the global leader in dialysis products and services, will maximize
 the value of sorbent therapy through rapid development of innovative
 products and services that would have been difficult to achieve as a small
 independent company," he continued. "The convergence of our respective
 resources will enhance the prospects for true innovative approaches,
 including portability and wearability, to further improve the service to
 patients requiring dialysis therapy worldwide."
 
     RSI is currently commercializing the Allient(R) Sorbent Hemodialysis
 System for chronic and acute hemodialysis applications. The Allient System
 will be the first dialysis system to bring SMARRT technology to the market,
 opening new treatment options to dialysis professionals and patients.
 
     The current RSI home use clinical study featuring the Allient System
 and sorbent technology will continue enrollment at multiple sites. The
 trial is designed to demonstrate patient ability to self-administer
 hemodialysis in the home using the FDA cleared system. In this research
 study, 25 dialysis participants will self-administer extended duration
 dialysis in the home.
 
     Morgan Stanley served as advisor to Renal Solutions for the
 transaction.
 
     About Renal Solutions, Inc
 
     Renal Solutions, Inc., a medical device and healthcare service company,
 is commercializing the Allient(R) Sorbent Hemodialysis System, a
 revolutionary technology/service solution for the chronic and acute
 dialysis market. The Allient System, brings SMARRT (Sorbent Management for
 Advanced Renal Replacement Therapy) therapy to the dialysis field, opening
 new treatment options to dialysis professionals and patients by virtue of
 its ability to provide short, standard or extended duration hemodialysis
 therapy using just 1 and 1/2 gallons of ordinary drinking water. Numerous
 clinical studies have shown that an increased cumulative dialysis dose
 results in better patient outcomes. The Allient System provides the
 increased dose advantage without the need for an independent water system
 or large volumes of sterile fluid. This translates into increased
 flexibility and convenience benefits.
 
     For more information about Renal Solutions visit the Company's website
 at www.renalsolutionsinc.com.
 
     This press release contains forward-looking statements, which if not
 based on historical facts, involve risks and uncertainties. Our actual
 results may differ materially from the results or events stated in the
 forward-looking statements, including, but not limited to, certain events
 not within the Company's control. Events which could cause results to
 differ include, failure to meet on-going developmental and manufacturing
 timelines, changing GMP requirements, the need for additional capital
 requirements, risks associated with the FDA/regulatory approval process,
 adverse changes to reimbursement for the Company's products/services and
 delays with respect to market acceptance of new products/services and
 technologies. Other risks may be detailed from time to time but the Company
 does not attempt to revise or update its forward- looking statements even
 if future experience or changes make it evident that any projected events
 or results expressed or implied therein will not be realized.
 
 
 SOURCE Renal Solutions, Inc.